Monday, 20 April 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 20 April 2026
News

GSK notches another RSV first

 Posted 20 April 2026 AM

After becoming the first to crack the Australian RSV market with Arexvy , GSK has notched another win with the vaccine becoming the first to be added to the National Immunisation Program (NIP) for older Australians.

More than two million Australians aged 75 and over, and Aboriginal and Torres Strait Islander people aged 60 years and over, will receive free Arexvy under a national push to reduce serious illness caused by RSV.

To see the whole article, please login

Popular

Nine leaders vie for MA board seats
Bosses crack the $40M Club
Pfizer names local as Interim MD
No TGA action after patient deaths
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (5)

Sales & Customer Relations (14)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (3)

Other (8)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home